August 2025
1. UPRIMNY C, von Guggenberg E, Sviridenko A, Bayerschmidt S, et al
   Diagnostic Performance of the (68)Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors.
   J Nucl Med. 2025 Aug 28:jnumed.125.269863. doi: 10.2967/jnumed.125.269863.
   

   >> Share

   
   June 2025
2. VON HINTEN J, Viering O, Bundschuh RA, Cagliyan F, et al
   Feasibility of Short-Term Redifferentiation in Patients with Radioactive Iodine-Refractory Metastatic Thyroid Cancer.
   J Nucl Med. 2025 Jun 5:jnumed.125.270055. doi: 10.2967/jnumed.125.270055.
   

   >> Share

   
   March 2025
3. WEIS H, Weindler J, Schmidt K, Hellmich M, et al
   Impact of Radioactive Iodine Treatment on Long-Term Relative Survival in Patients with Papillary and Follicular Thyroid Cancer: A SEER-Based Study Covering Histologic Subtypes and Recurrence Risk Categories.
   J Nucl Med. 2025 Mar 13:jnumed.124.269091. doi: 10.2967/jnumed.124.269091.
   

   >> Share

   
   January 2025
4. BARBRY F, Chevalier B, Beron A, Lion G, et al
   Redifferentiation of a RET-Fusion, Radioiodine-Refractory, Differentiated Thyroid Cancer with Selpercatinib: Flip-Flop Between [(18)F]FDG PET/CT and (131)I Posttreatment Scanning.
   J Nucl Med. 2025 Jan 16:jnumed.124.268539. doi: 10.2967/jnumed.124.268539.
   

   >> Share

   
   
5. VON GUGGENBERG E, di Santo G, Uprimny C, Bayerschmidt S, et al
   Safety, Biodistribution, and Radiation Dosimetry of the (68)Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors.
   J Nucl Med. 2025 Jan 16:jnumed.124.268877. doi: 10.2967/jnumed.124.268877.
   

   >> Share

   
   July 2024
6. AL-NAQEEB G, Munger E, Ramanathan AL, Makarewicz A, et al
   Paraplegic Patient with Metastatic Papillary Thyroid Cancer: A Multidisciplinary Approach to Radioactive Iodine Therapy Safety and Efficacy Strategy.
   J Nucl Med. 2024 Jul 11:jnumed.123.266955. doi: 10.2967/jnumed.123.266955.
   

   >> Share

   
   April 2024
7. GREENSPAN BS, Hofman MS, Buscombe J
   The Accomplishments and Legacy of Saul Hertz, MD.
   J Nucl Med. 2024;65:659-663.
   

   >> Share

   
   March 2024
8. KIM KJ, Choi J, Kim KJ, Song E, et al
   Cancer Risk in Graves Disease with Radioactive (131)I Treatment: A Nationwide Cohort Study.
   J Nucl Med. 2024 Mar 28:jnumed.123.266531. doi: 10.2967/jnumed.123.266531.
   

   >> Share

   
   
9. GREENSPAN BS, Hofman MS, Buscombe J
   Commentary on "Radioactive Iodine: A Living History".
   J Nucl Med. 2024;65:495.
   

   >> Share

   
   December 2023
10. VENTURA D, Dittmann M, Buther F, Schafers M, et al
    Diagnostic Performance of [(18)F]TFB PET/CT Compared with Therapeutic Activity [(131)I]Iodine SPECT/CT and [(18)F]FDG PET/CT in Recurrent Differentiated Thyroid Carcinoma.
    J Nucl Med. 2023 Dec 21:jnumed.123.266513. doi: 10.2967/jnumed.123.266513.
    

    >> Share

    
    November 2023
11. GUNTHER T, Holzleitner N, Viering O, Beck R, et al
    Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [(68)Ga]Ga-DOTA-CCK-66 PET/CT in 2 Patients with Medullary Thyroid Cancer.
    J Nucl Med. 2023 Nov 9:jnumed.123.266537. doi: 10.2967/jnumed.123.266537.
    

    >> Share

    
    
12. VIERING O, Gunther T, Holzleitner N, Dierks A, et al
    CCK(2) Receptor-Targeted PET/CT in Medullary Thyroid Cancer Using [(68)Ga]Ga-DOTA-CCK-66.
    J Nucl Med. 2023 Nov 2:jnumed.123.266380. doi: 10.2967/jnumed.123.266380.
    

    >> Share

    
    October 2023
13. LASCHINSKY C, Theurer S, Herold T, Rawitzer J, et al
    Molecular Markers Are Associated with Onset of Radioiodine Refractoriness in Patients with Papillary Thyroid Carcinoma.
    J Nucl Med. 2023 Oct 26:jnumed.123.266044. doi: 10.2967/jnumed.123.266044.
    

    >> Share

    
    June 2023
14. ENKE JS, Bundschuh RA, Wienand G, Reitsam NG, et al
    Somatostatin Receptor Antagonists as a Theranostic Option in Iodine-Refractory Thyroid Carcinoma.
    J Nucl Med. 2023 Jun 15:jnumed.123.265639. doi: 10.2967/jnumed.123.265639.
    

    >> Share

    
    April 2023
15. TAPROGGE J, Abreu C, Yusuf S, Ainsworth G, et al
    The Role of Pretherapy Quantitative Imaging and Dosimetry in Radioiodine Therapy for Advanced Thyroid Cancer.
    J Nucl Med. 2023 Apr 28:jnumed.122.264913. doi: 10.2967/jnumed.122.264913.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share